Clinical trials: Schizophrenia and Disorders With Psychotic Feature
Psychotic Depression, Severe Major Depression With Psychotic Features
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by…
- Conditions
- Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
- Trial name
- NCT00637494
- Testing
- mifepristone
- Where
- 42 sites in United States
- Volunteers
- 292 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Schizoaffective Disorder
Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia
The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.
- Trial name
- NCT01324167
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University WanFang Hospital
Schizophrenia, Mental Disorders
Effects of Delta-9-THC and Iomazenil in Healthy Humans
The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG).
- Conditions
- Schizophrenia, Mental Disorders, Psychotic Disorders
- Trial name
- NCT00982982
- Testing
- THC and Iomazenil
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.
A multicenter, randomized, double-blind, placebo-controlled, dose-increasing phase Ib/II clinical trial to evaluate the safety, tolerance and pharmacokinetic characteristics of JX11502MA capsules administered multiple times in…
- Trial name
- NCT06356389
- Testing
- JX11502MA
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Jingxin Pharmaceutical Co., Ltd.
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Psychosis
Minnesota Community-Based Cognitive Training in Early Psychosis
The purpose of this study is to determine whether cognitive training exercises can improve cognitive functioning in young patients with recent-onset psychosis who are being treated in community mental health settings using the…
- Conditions
- Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- Mini-COTES (NCT03079024)
- Testing
- Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Minnesota
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Schizophrenia, Schizophrenia and Disorders With Psychotic Features
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the…
- Conditions
- Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
- Trial name
- NCT02307396
- Testing
- Olanzapine, Amisulpride, Risperidone
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Technical University of Munich
Schizophrenia, Schizoaffective Disorder
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
The overarching purpose of this pilot study is to collect preliminary data regarding the variability of weight gain associated with lurasidone (Latuda©) treatment of antipsychotic naive children and adolescents in order to inform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Trial name
- NCT01731119
- Testing
- Latuda©
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Insomnia, Psychosis
CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes
The goal of this project is to develop guidelines for the clinical tailoring of Cognitive Behavioral Therapy for Insomnia (CBT-I) for Veterans with psychotic disorders and insomnia, and to test the acceptability, feasibility, and…
- Trial name
- CBT-I (NCT02535923)
- Testing
- Cognitive Behavioral Therapy-Insomnia, Health and Wellness
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- VA Office of Research and Development
Depression, Depressive Disorders
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with Org 34517.
- Conditions
- Depression, Depressive Disorders, Psychotic Disorders
- Trial name
- Hermes (NCT00212797)
- Testing
- Org 34517
- Volunteers
- 273 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Schizoaffective Disorder
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
- Trial name
- NCT00312598
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder, Psychotic Disorders
Safety Study of ORG 34517 for Major Depression With Psychotic Features
Patients suffering from Major Depressive Disorder with Psychotic features who have received no changes in their medications in the previous two weeks will receive "usual" treatment of antidepressants, antipsychotics and/or mood…
- Trial name
- NCT00226278
- Testing
- ORG 34517
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Bipolar Disorder
A Biological Signature for the Early Differential Diagnosis of Psychosis
Schizophrenia (SZ) and mood disorders (BD, MDD) are among the most disabling disorders worldwide, with a relevant social, functional, and economic burden.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT06515522
- Testing
- differential diagnosis
- Volunteers
- 1,850 people
- Sponsor
- IRCCS San Raffaele
Depressive Disorders, Psychotic Disorders
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized…
- Conditions
- Depressive Disorders, Psychotic Disorders, Depression
- Trial name
- NCT00844922
- Testing
- SCH 900636
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia, Schizoaffective Disorder
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
The aim of the study is to examine whether determining treatment strategies based upon Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome in patients with psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
- Trial name
- NCT01878513
- Testing
- risperidone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Northwell Health
Bipolar I Disorder, Unspecified, With Psychotic Features, Bipolar I Disorder, Unspecified, Without Psychotic Features
Psychosis and Affective Research Domains and Intermediate Phenotypes
The objective of this multi-site research collaboration is to test the manifestation and distribution of biological markers for psychosis and affect dimensions across the schizophrenia/bipolar (SZ-BD) diagnostic boundary, and to…
- Trial name
- PARDIP (NCT02218853)
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center